A new federally funded research effort in Rochester is aiming to tackle one of the biggest gaps in treating age-related macular degeneration — stopping vision loss before it starts. Researchers at ...

DURAVYU has established safety and efficacy data from both Phase 1 and 2 trials in wet AMD and DME that demonstrate stability in vision and anatomical control with a single dose of DURAVYU. No ...

ORLANDO, Fla. (Ivanhoe Newswire) - There are two types of macular degeneration: dry and wet. Dry age-related macular degeneration is the most common type — it happens when small deposits form under ...

Following a year of uncertainty surrounding federal biomedical research funding, BrightFocus Foundation provides critical support for innovative brain and eye research BrightFocus Foundation today ...

VLTR-559 demonstrates sustained anti-VEGF activity and favorable safety at target clinical dosefor treatment of wetage-related macular ...

MingMed Biotechnology Co., Ltd, a biomedical firm focused on the discovery and development of novel therapeutics across multiple therapeutic areas, announced positive results from its Phase II ...

In Editorial, The New England Journal of Medicine Calls Science Corporation's PRIMA Implant "The First Treatment to Restore Vision" In Patients Suffering From Advanced Geographic Atrophy Due to ...

Australian researchers have for the first time pinpointed specific genetic changes that increase the risk of severe, sight-threatening forms of age-related macular degeneration (AMD). A new study, ...

BrightFocus Foundation today announced $15.2 million in new research grants for Alzheimer’s disease, macular degeneration, and glaucoma, reinforcing its commitment to advancing scientific discovery ...